Cosmo N.V. (COPN.SW) Stock
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Peer Comparison
About Cosmo N.V.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
Cosmo N.V. is led by CEO Giovanni di Napoli, employs 325 people, headquartered in Dublin, IE, publicly traded since 2007.
over the past 52 weeks the stock has ranged between $55.20 and $129.40, and currently trades 52.9% below its 52-week high.
Official website: www.cosmopharma.com